| 1 |
Han B, Zheng R, Zeng H, et al.Cancer incidence and mortality in China,2022[J].J Natl Cancer Cent,2024,4(1):47-53.
|
| 2 |
Ling S, Jiang G, Que Q, et al.Liver transplantation in patients with liver failure: twenty years of experience from China[J].Liver Int,2022,42(9):2110-2116.
|
| 3 |
中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组.中国肝癌肝移植临床实践指南(2021 版)[J/CD].中华移植杂志:电子版,2021,15(6):321-328.
|
| 4 |
中华人民共和国国家卫生健康委员会医政司.原发性肝癌诊疗指南(2024 年版)[J].协和医学杂志,2024,15(3):532-559.
|
| 5 |
Kwong AJ, Kim WR, Lake JR, et al.OPTN/SRTR 2022 annual data report: liver[J].Am J Transplant, 2024, 24(2S1): S176-S265.
|
| 6 |
Chen J, Shen T, Li J, et al.Clinical practice guideline on liver transplantation for hepatocellular carcinoma in China (2021 edition)[J].Chin Med J (Engl),2022,135(24):2911-2913.
|
| 7 |
Sapisochin G, Bruix J.Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J].Nat Rev Gastroenterol Hepatol,2017,14(4):203-217.
|
| 8 |
Xu X, Lu D, Ling Q, et al.Liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J].Gut,2016,65(6): 1035-1041.
|
| 9 |
谢琴芬, 郑树森.肝癌患者肝移植后的免疫抑制剂应用[J].中华器官移植杂志,2013,34(9):573-575.
|
| 10 |
Rodriguez-peralvarez M, Tsochatzis E, Naveas MC, et al.Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J].J Hepatol,2013,59(6):1193-1199.
|
| 11 |
Vivarelli M, Cucchetti A, La Barba G, et al.Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors:reassessment of risk factors for tumor recurrence[J].Ann Surg,2008,248(5):857-862.
|
| 12 |
Vivarelli M, Cucchetti A, Piscaglia F, et al.Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma:key role of immunosuppression[J].Liver Transpl,2005,11(5):497-503.
|
| 13 |
Fan GH, Zhang CZ, Gao FQ, et al.A mixed blessing for liver transplantation patients -Rapamycin[J].Hepatobiliary Pancreat Dis Int,2023,22(1):14-21.
|
| 14 |
Kim WR, Lake JR,Smith JM,et al.OPTN/SRTR 2016 annual data report: liver[J].Am J Transplant, 2018, 18(Suppl 1): S172-S253.
|
| 15 |
Shenoy S, Hardinger KL, Crippin J, et al.Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective,randomized, single-center trial [J].Transplantation, 2007, 83(10):1389-1392.
|
| 16 |
Harper SJ, Gelson W, Harper IG, et al.Switching to sirolimusbased immune suppression after liver transplantation is safe and effective: a single-center experience[J].Transplantation, 2011, 91(1):128-132.
|
| 17 |
Buchholz BM, Ferguson JW, Schnitzbauer AA, et al.Randomized sirolimus-based early calcineurin inhibitor reduction in liver transplantation:impact on renal function[J].Transplantation,2020,104(5):1003-1018.
|
| 18 |
Kim DS, Yoon YI, Kim BK, et al.Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation[J].Hepatol Int,2024,18(2):299-383.
|
| 19 |
Andrews JC, Schunemann HJ, Oxman AD, et al.GRADE guidelines:15.Going from evidence to recommendation-determinants of a recommendation′s direction and strength[J].J Clin Epidemiol,2013,66(7):726-735.
|
| 20 |
Guyatt G, Oxman AD, Akl EA, et al.GRADE guidelines: 1.Introduction-GRADE evidence profiles and summary of findings tables[J].J Clin Epidemiol,2011,64(4):383-394.
|
| 21 |
中国医师协会器官移植医师分会肝移植学组, 中华医学会器官移植学分会肝移植学组.西罗莫司在肝癌肝移植中应用的中国专家共识(2020 版)[J].中华消化外科杂志,2020,19(6):589-597.
|
| 22 |
Bob P, Chris B, Dave S, et al.Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009)[EB/OL].[2024-12-13].https:/ /www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidencemarch-2009.
|
| 23 |
Halloran PF.Immunosuppressive drugs for kidney transplantation[J].N Engl J Med,2004,351(26):2715-2729.
|
| 24 |
Watson CJ, Friend PJ, Jamieson NV, et al.Sirolimus: a potent new immunosuppressant for liver transplantation[J].Transplantation,1999,67(4):505-509.
|
| 25 |
Mchenry CR, Rosen IB, Walfish PG, et al.Oral calcium load test:diagnostic and physiologic implications in hyperparathyroidism[J].Surgery,1990,108(6):1026-1031; discussion 1032.
|
| 26 |
Mcalister VC, Peltekian KM, Malatjalian DA, et al.Orthotopic liver transplantation using low-dose tacrolimus and sirolimus[J].Liver Transpl,2001,7(8):701-708.
|
| 27 |
Dunkelberg JC, Trotter JF, Wachs M, et al.Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications[J].Liver Transpl, 2003, 9(5):463-468.
|
| 28 |
Zhou J, Fan J, Wang Z, et al.Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience[J].World J Gastroenterol,2006,12(19):3114-3118.
|
| 29 |
Mckenna GJ, Trotter JF.Sirolimus--it doesn′t deserve its bad Rap(a)[J].J Hepatol,2012,56(1):285-287.
|
| 30 |
Geissler EK, Schnitzbauer AA,Zulke C,et al.Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized,multicenter, open-label phase 3 trial[J].Transplantation, 2016,100(1):116-125.
|
| 31 |
Schnitzbauer AA, Zuelke C, Graeb C, et al.A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma[J].BMC Cancer,2010,10:190.
|
| 32 |
Zaghla H, Selby RR, Chan LS, et al.A comparison of sirolimus vs.calcineurin inhibitor-based immunosuppressive therapies in liver transplantation[J].Aliment Pharmacol Ther, 2006, 23(4): 513-520.
|
| 33 |
Saner FH, Cicinnati VR, Sotiropoulos G, et al.Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation[J].Liver Int,2012,32(2):179-188.
|
| 34 |
中华医学会器官移植学分会,中国医师协会器官移植医师分会,等.中国肝移植受者肾损伤管理临床实践指南(2023 版)[J/CD].中华移植杂志:电子版,2023,17(6):321-331.
|
| 35 |
Cotterell AH, Fisher RA, King AL, et al.Calcineurin inhibitorinduced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent[J].Clin Transplant,2002,16(Suppl 7): S49-S51.
|
| 36 |
Teperman L, Moonka D, Sebastian A, et al.Calcineurin inhibitorfree mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial[J].Liver Transpl,2013,19(7):675-689.
|
| 37 |
Ju WQ, Guo ZY, Liang WH, et al.Sirolimus conversion in liver transplantrecipientswithcalcineurininhibitor-induced complications: efficacy and safety[J].Exp Clin Transplant, 2012,10(2):132-135.
|
| 38 |
Yang YJ, Chen DZ, Li LX, et al.Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency[J].Transplant Proc,2008,40(5):1541-1544.
|
| 39 |
Campbell MS, Rai J, Kozin E, et al.Effects of sirolimus vs.calcineurin inhibitors on renal dysfunction after orthotopic liver transplantation[J].Clin Transplant,2007,21(3):377-384.
|
| 40 |
Perrakis A, Schwarz K, Yedibela S, et al.Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications,safety, and outcome[J].Transplant Proc, 2011, 43(10): 3702-3707.
|
| 41 |
Tsai KF, Li LC, Hsu CN, et al.Effects of conversion from calcineurin inhibitors to sirolimus or everolimus on renal function and possible mechanisms in liver transplant recipients [ J].J Clin Pharmacol,2019,59(3):326-334.
|
| 42 |
Kawahara T, Asthana S, Kneteman NM.m-TOR inhibitors: what role in liver transplantation?[J].J Hepatol, 2011, 55(6): 1441-1451.
|
| 43 |
Sahin F, Kannangai R, Adegbola O, et al.mTOR and P70 S6 kinase expression in primary liver neoplasms[J].Clin Cancer Res,2004,10(24):8421-8425.
|
| 44 |
Lu EW, Deftos M,Tighe H,et al.Generation and characterization of two monoclonal self-associating IgG rheumatoid factors from a rheumatoid synovium[J].Arthritis Rheum, 1992, 35(1): 101-105.
|
| 45 |
Semela D, Piguet AC, Kolev M, et al.Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma[J].J Hepatol,2007,46(5):840-848.
|
| 46 |
Guba M, Yezhelyev M, Eichhorn ME, et al.Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF[J].Blood,2005,105(11):4463-4469.
|
| 47 |
Guba M, Graeb C, Jauch KW, et al.Pro-and anti-cancer effects of immunosuppressive agents used in organ transplantation [ J].Transplantation,2004,77(12):1777-1782.
|
| 48 |
Lee KW, Kim SH, Yoon KC, et al.Sirolimus prolongs survival after living donor liver transplantation for hepatocellular carcinoma beyond milan criteria: a prospective, randomised, open-label, multicentre phase 2 trial[J].J Clin Med,2020,9(10):3264.
|
| 49 |
Menon KV, Hakeem AR, Heaton ND.Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J].Aliment Pharmacol Ther, 2013, 37(4):411-419.
|
| 50 |
Yanik EL, Chinnakotla S, Gustafson SK, et al.Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma[J].Liver Transpl,2016,22(5):627-634.
|
| 51 |
Tejedor-Tejada J, Alonso-Martín C, Almohalla-Álvarez C, et al.Immunosuppressive treatment with mTOR inhibitors for malignancies after liver transplantation: long-term survival retrospective analysis[J].Transplant Proc,2020,52(5):1507-1510.
|
| 52 |
Zhang G, Duan B, Li G.mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: a systematic review and meta-analysis[J].Clin Transplant, 2022, 36(12): e14823.
|
| 53 |
Yan X, Huang S, Yang Y, et al.Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis[J].Liver Transpl, 2022, 28(6):1063-1077.
|
| 54 |
De Visser KE, Joyce JA.The evolving tumor microenvironment:From cancer initiation to metastatic outgrowth[J].Cancer Cell,2023,41(3):374-403.
|
| 55 |
张琳成, 詹启帆, 赵禹迪,等.肝癌肝移植术后免疫抑制方案的网状荟萃分析[J/CD].中华移植杂志:电子版, 2023, 17(6):362-371.
|
| 56 |
Zhou J, Wang Z,Wu ZQ,et al.Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria[J].Transplant Proc, 2008,40(10):3548-3553.
|
| 57 |
Ling S, Feng T, Zhan Q, et al.Sirolimus-based immunosuppression improves outcomes in liver transplantation recipients with hepatocellular carcinoma beyond the Hangzhou criteria[J].Ann Transl Med,2020,8(4):80.
|
| 58 |
Su RY, Ling SB, Shan QN, et al.Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma: a single-arm, multicenter, prospective study[J].Hepatobiliary Pancreat Dis Int,2022,21(2):106-112.
|
| 59 |
倪彦彬, 栗光明, 王福顺, 等.单中心肝细胞癌患者肝移植术后长期生存情况分析[J].中华普通外科杂志, 2023, 38(9): 641-647.
|
| 60 |
Xu SL, Zhang YC, Wang GY, et al.Survival analysis of sirolimusbased immunosuppression in liver transplantation in patients with hepatocellular carcinoma [J].Clin Res Hepatol Gastroenterol,2016,40(6):674-681.
|
| 61 |
Ling S, Zhan Q, Jiang G, et al.E2F7 promotes mammalian target of rapamycin inhibitor resistance in hepatocellular carcinoma after liver transplantation[J].Am J Transplant,2022,22(10):2323-2336.
|
| 62 |
Zhang L, Zhou W, Zheng S, et al.An E2F7/TSC1-based model for predicting the efficacy of sirolimus after liver transplantation for hepatocellular carcinoma beyond the Milan criteria[J].Chin Med J(Engl),2024,137(16):1973-1975.
|
| 63 |
Perl A.mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging[J].Ann N Y Acad Sci,2015,1346(1):33-44.
|
| 64 |
Houde VP, Brule S, Festuccia WT, et al.Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue[J].Diabetes,2010,59(6):1338-1348.
|
| 65 |
Chang JW, Yang HH, Lin NC, et al.Risk factors for fractures following liver transplantation: a population-based cohort study[J].Ann Med,2023,55(1):2230871.
|
| 66 |
Zhang L, Liu P, Zhuang L, et al.mTOR inhibitor reduces nontumour-related death in liver transplantation for hepatocellular carcinoma[J].Mol Biomed,2024,5(1):9.
|
| 67 |
Hu AB, Wu LW, Tai Q, et al.Safety and efficacy of four steroidminimization protocols in liver transplant recipients:3-year follow-up in a single center[J].J Dig Dis,2013,14(1):38-44.
|
| 68 |
Toso C, Merani S, Bigam DL, et al.Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma[J].Hepatology, 2010,51(4):1237-1243.
|
| 69 |
Liang W, Wang D, Ling X, et al.Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis[J].Liver Transpl, 2012, 18(1): 62-69.
|
| 70 |
Zhang ZH, Li LX, Li P, et al.Sirolimus in liver transplant recipients with hepatocellular carcinoma: an updated meta-analysis[J].J Invest Surg,2019,32(7):632-641.
|
| 71 |
Alamo JM, Bernal C, Marin LM, et al.Antitumor efficacy of mammalian target of rapamycin inhibitor therapy in liver transplant recipients with oncological disease: a case-control study [ J].Transplant Proc,2012,44(7):2089-2092.
|
| 72 |
Chinnakotla S, Davis GL,Vasani S,et al.Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation[J].Liver Transpl,2009,15(12):1834-1842.
|
| 73 |
Zimmerman MA, Trotter JF, Wachs M, et al.Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma[J].Liver Transpl,2008,14(5):633-638.
|
| 74 |
Schnitzbauer AA, Filmann N, Adam R, et al.mTOR inhibition is most beneficial after liver transplantation for hepatocellular carcinoma in patients with active tumors[J].Ann Surg, 2020, 272(5): 855-862.
|
| 75 |
Abdelmalek MF, Humar A, Stickel F, et al.Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial[J].Am J Transplant,2012, 12(3):694-705.
|
| 76 |
Asrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial[J].Am J Transplant,2014,14(2):356-366.
|
| 77 |
Mulder MB, Van Hoek B, Van Den Berg AP, et al.Three-year results of renal function in liver transplant recipients on low-dose sirolimus and tacrolimus: a multicenter, randomized, controlled trial[J].Liver Transpl,2023,29(2):184-195.
|
| 78 |
Schnitzbauer AA, Sothmann J, Baier L, et al.Calcineurin inhibitor free de novo immunosuppression in liver transplant recipients with pretransplant renal impairment:results of a pilot study (PATRON07)[J].Transplantation,2015,99(12):2565-2575.
|
| 79 |
Wang Z, Zhou J, Fan J, et al.Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma[J].Clin Cancer Res, 2008, 14(16):5124-5130.
|
| 80 |
Ji S, Feng L, Fu Z, et al.Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology[J].Sci Transl Med,2023,15(706): eadg3358.
|
| 81 |
Yu J, Ling S, Hong J, et al.TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma[J].J Immunother Cancer,2023,11(11): e007479.
|
| 82 |
Bang K, Casadei-gardini A, Yoo C, et al.Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation[J].Cancer Med,2023,12(3):2572-2579.
|
| 83 |
Kudo M, Finn RS, Qin S, et al.Lenvatinib versus sorafenib in firstline treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial[J].Lancet, 2018, 391(10126):1163-1173.
|
| 84 |
Invernizzi F, Iavarone M, Zavaglia C, et al.Experience with early sorafenib treatment with mTOR inhibitors in hepatocellular carcinoma recurring after liver transplantation[J].Transplantation, 2020, 104(3):568-574.
|
| 85 |
Abdelmalek MF, Humar A, Stickel F, et al.Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial[J].Am J Transplant,2012, 12(3):694-705.
|
| 86 |
Charlton M, Levitsky J, Aqel B, et al.International liver transplantation society consensus statement on immunosuppression in liver transplant recipients[J].Transplantation,2018,102(5):727-743.
|
| 87 |
Colmenero J, Tabrizian P, Bhangui P, et al. De novo malignancy after liver transplantation: risk assessment, prevention, and management-guidelines from the ILTS-SETH consensus conference[J].Transplantation,2022,106(1): e30-e45.
|
| 88 |
Garbe C, Amaral T, Peris K, et al.European consensus-based interdisciplinary guideline for melanoma.Part 2: treatment -update 2022[J].Eur J Cancer,2022,170:256-284.
|
| 89 |
Stallone G, Schena A, Infante B, et al.Sirolimus for Kaposi′s sarcoma in renal-transplant recipients[J].N Engl J Med,2005,352(13):1317-1323.
|
| 90 |
Mumtaz K, Faisal N, Marquez M, et al.Post-transplant lymphoproliferative disorder in liver recipients: Characteristics,management, and outcome from a single-centre experience with >1 000 liver transplantations[J].Can J Gastroenterol Hepatol,2015,29(8):417-422.
|
| 91 |
Thimonier E, Guillaud O, Walter T, et al.Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease[J].Clin Transplant,2014,28(12):1339-1348.
|
| 92 |
Vivarelli M, Dazzi A, Zanello M, et al.Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma[J].Transplantation,2010,89(2):227-231.
|
| 93 |
US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.Common terminology criteria for adverse events (CTCAE) version 5 [EB/OL].(2017-11-27)[2024-12-13 ].https:/ /ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf.
|
| 94 |
危荣沥, 徐骁.肝细胞癌肝移植分子分型与精准治疗[J/CD].实用器官移植电子杂志,2019,7(1):62.
|
| 95 |
Kaplan B, Qazi Y, Wellen JR.Strategies for the management of adverse events associated with mTOR inhibitors[J].Transplant Rev(Orlando),2014,28(3):126-133.
|
| 96 |
Silva AC, Nogueira P, Machado MV.Hepatic steatosis after liver transplantation: a systematic review and meta-analysis[J].Liver Transpl,2023,29(4):431-448.
|
| 97 |
Fan G, Zhang C, Wei X, et al.NEAT1/hsa-miR-372-3p axis participates in rapamycin-induced lipid metabolic disorder[J].Free Radic Biol Med,2021,167:1-11.
|
| 98 |
Busaidy NL, Farooki A, Dowlati A, et al.Management of metabolic effects associated with anticancer agents targeting the PI3K-AktmTOR pathway[J].J Clin Oncol,2012,30(23):2919-2928.
|
| 99 |
Nguyen LS, Vautier M, Allenbach Y, et al.Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation[J].Drug Saf,2019,42(7):813-825.
|
| 100 |
蔡涛, 曹经琳, 窦剑, 等.肝移植术后血小板减少的诊断与治疗同步[J].器官移植,2024,15(6):964-969.
|
| 101 |
Sofroniadou S, Kassimatis T, Goldsmith D.Anaemia, microcytosis and sirolimus--is iron the missing link? [ J].Nephrol Dial Transplant,2010,25(5):1667-1675.
|
| 102 |
Mcdonald MA, Gustafsson F, Almasood A, et al.Sirolimus is associated with impaired hematopoiesis in heart transplant patients?A retrospective analysis[J].Transplant Proc,2010,42(7):2693-2696.
|
| 103 |
中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤相关贫血诊治专家共识(2023版)[J].中华肿瘤杂志,2023,45(12):1032-1040.
|
| 104 |
中国抗癌协会肿瘤支持治疗专业委员会, 中国抗癌协会肿瘤临床化疗专业委员会.肿瘤化疗导致的中性粒细胞减少诊治专家共识(2019 版)[J].中国肿瘤临床,2019,46(23):876-882.
|
| 105 |
中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会.中国肿瘤药物相关血小板减少诊疗专家共识(2023 版)[J].中华医学杂志,2023,103(33):2579-2590.
|
| 106 |
Letavernier E, Legendre C.mToR inhibitors-induced proteinuria:mechanisms, significance, and management[J].Transplant Rev(Orlando),2008,22(2):125-130.
|
| 107 |
Bruschi M, Granata S, Candiano G, et al.Proteomic changes induced by the immunosuppressant everolimus in human podocytes[J].Int J Mol Sci,2024,25(13):7336.
|
| 108 |
Arnau A, Ruiz JC,Rodrigo E,et al.Is proteinuria reversible,after withdrawal of mammalian target of rapamycin inhibitors?[ J].Transplant Proc,2011,43(6):2194-2195.
|
| 109 |
Fairbanks KD, Eustace JA, Fine D, et al.Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus[J].Liver Transpl, 2003, 9(10): 1079-1085.
|
| 110 |
Morcos A, Nair S, Keane MP, et al.Interstitial pneumonitis is a frequent complication in liver transplant recipients treated with sirolimus[J].Ir J Med Sci,2012,181(2):231-235.
|
| 111 |
陈方, 陶兴茹, 段彦彦.西罗莫司相关性间质性肺炎的临床特点分析[J].河南医学研究,2023,32(10):1782-1786.
|
| 112 |
Morath C, Schwenger V, Ksoll-Rudek D, et al.Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors[J].Transplant Proc,2007,39(1):99-102.
|
| 113 |
Garrean S, Massad MG, Tshibaka M, et al.Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients[J].Clin Transplant,2005,19(5):698-703.
|
| 114 |
中国器官移植发展基金会器官移植受者健康管理专家委员会,中国医师协会器官移植医师分会, 中华医学会器官移植学分会, 等.肝移植受者雷帕霉素靶蛋白抑制剂临床应用中国专家共识(2023 版)[J/CD].中华移植杂志: 电子版, 2023,17(4):193-204.
|
| 115 |
Ventura-Aguiar P, Campistol JM, Diekmann F.Safety of mTOR inhibitors in adult solid organ transplantation[J].Expert Opin Drug Saf,2016,15(3):303-319.
|
| 116 |
Cooper M, Wiseman AC, Zibari G, et al.Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials[J].Clin Transplant, 2013, 27(6): E625-E635.
|
| 117 |
Roine E, Bjork IT, Oyen O.Targeting risk factors for impaired wound healing and wound complications after kidney transplantation[J].Transplant Proc,2010,42(7):2542-2546.
|
| 118 |
Montalti R, Mimmo A, Rompianesi G, et al.Early use of mammalian target of rapamycin inhibitors is an independent risk factor for incisional hernia development after liver transplantation[J].Liver Transpl,2012,18(2):188-194.
|
| 119 |
Campistol JM, De Fijter JW, Flechner SM, et al.mTOR inhibitorassociated dermatologic and mucosal problems[J].Clin Transplant,2010,24(2):149-156.
|
| 120 |
Sanchez-Fructuoso AI, Ruiz JC, Perez-Flores I, et al.Comparative analysis of adverse events requiring suspension of mTOR inhibitors:everolimus versus sirolimus[J].Transplant Proc, 2010, 42(8):3050-3052.
|